2002065357

25 OCT 2002

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/83512 A1

(51) International Patent Classification[7]: C07J 41/00, 71/00, A61K 31/57, 31/58, 31/56, A61P 11/06, 37/08

(21) International Application Number: PCT/CA01/00581

(22) International Filing Date: 30 April 2001 (30.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/200,617 28 April 2000 (28.04.2000) US

(71) Applicant *(for all designated States except US)*: **INFLAZYME PHARMACEUTICALS LIMITED** [CA/CA]; Suite 425, 5600 Parkwood Way, Richmond, British Columbia V6V 2M2 (CA).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **RAYMOND, Jeffery, R.** [CA/CA]; 4809 Blenheim Street, Vancouver, British Columbia V6L 3A8 (CA). **KASSERRA, Claudia, E.** [CA/CA]; 4327 Dollar Road, North Vancouver, British Columbia V7G 1A9 (CA). **SHEN, Yaping** [CA/CA]; 21-2458 Pitt River Road, Port Coquitlam, British Columbia V3C 6J7 (CA).

(74) Agents: **NASSIF, Omar, A.** et al.; Gowling Lafleur Henderson LLP, Suite 4900, Commerce Court West, Toronto, Ontario M5L 1J3 (CA).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

162162

(54) Title: 3-NITROGEN-6,7-DIOXYGEN STEROIDS AND USES RELATED THERETO



(I)

(57) Abstract: A compound of formula (I) and pharmaceutical acceptable salts, solvates, stereoisomers and prodrugs thereof, in isolation or in mixture, wherein, independently at each occurrence: R^1 and R^2 are selected from hydrogen, oxygen so as to form nitro or oxime, amino, sulfate, and sulfonic acid, and organic groups having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen, phosphorous, silicon, and sulfur, where R^1 and R^2 may, together with the N to which they are both bonded, form a heterocyclic structure that may be part of an organic group having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen and silicon, and where R^1 may be a 2, or 3 atom chain to numeral 2 so that —N-R^1 - forms part of a fused bicyclic structure to ring A; R^3 and R^4 are selected from direct bonds to 6 and 7 respectively so as to form carbonyl groups, hydrogen, or a protecting group such that R^3 and/or R^4 is part of hydroxyl or carbonyl protecting group; numerals 1 through 17 each represent a carbon having substitution as described. The compounds may be formulated into pharmaceutical compositions, and used in the treatment and/or prevention of various conditions, including inflammation, asthma, an allergic disease, chronic obstructive pulmonary disease, atopic dermatitis, solid tumors, AIDS, ischemia, and cardiac arrhythmias.

WO 01/83512 A1

ACTION